<a href="https://laohu8.com/S/XLO">Xilio Therapeutics</a> Announces New Clinical Data for Tumor-Activated Immunotherapies at SITC 2025 Annual Meeting
Xilio Therapeutics Inc., a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced multiple upcoming presentations at the Society for Immunotherapy of Cancer $(SITC)$ 40th Annual Meeting, scheduled for November 6-9, 2025, at the Gaylord National Convention Center in National Harbor, Maryland. The company will present new clinical data on vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, and efarindodekin alfa (XTX301), a tumor-activated IL-12. Additionally, preclinical data on Xilio's masked T cell engager programs will be showcased. Specific poster presentations include an analysis of ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable metastatic colorectal cancer, pharmacodynamic data from the first-in-human phase 1 study of XTX301 in advanced solid tumors, and data on masked T cell engagers designed for synthetic anti-tumor immunity with favorable tolerability. The results will be presented during the SITC Annual Meeting and have not yet been disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539345-en) on October 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.